# A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

> **NCT06997627** · PHASE1,PHASE2 · RECRUITING · sponsor: **GC Biopharma Corp** · enrollment: 120 (estimated)

## Conditions studied

- Tetanus-diphtheria-acellular Pertussis (Tdap)

## Interventions

- **BIOLOGICAL:** GC3111B
- **BIOLOGICAL:** Boostrix®

## Key facts

- **NCT ID:** NCT06997627
- **Lead sponsor:** GC Biopharma Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-05
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06997627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06997627, "A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06997627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*